HC Wainwright & Co. Reiterates Buy on Sana Biotechnology, Maintains $12 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Emily Bodnar has reiterated a Buy rating on Sana Biotechnology (NASDAQ:SANA) with a maintained price target of $12.
May 09, 2024 | 7:22 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Sana Biotechnology's stock rating was reiterated as Buy by HC Wainwright & Co. with a price target of $12.
The reiteration of a Buy rating by a reputable analyst firm like HC Wainwright & Co. typically signals continued confidence in the company's potential, likely encouraging investors and potentially leading to a positive short-term impact on the stock price. The maintenance of a $12 price target suggests the firm's analysis supports a strong upside potential from current levels.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100